Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Talquetamab · Talvey

Bispecific antibody · Immune activation, directed at G protein-coupled receptor class C group 5 member D (GPRC5D) and CD3 receptor on T-cells · developed by Janssen Biotech

Approved FDA, Aug 2023
JNJ Developer
1 Registered trials

What is Talquetamab?

Talquetamab is a bispecific T-cell engaging antibody that binds GPRC5D on multiple myeloma cells and CD3 on T-cells, bringing T-cells into contact with tumor cells to trigger their lysis and cytokine release. It is studied in relapsed or refractory multiple myeloma and cytokine release syndrome.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Talvey, JNJ 64407564, JNJ-64407564, JNJ64407564
Drug type
Bispecific antibody
Targets
G protein-coupled receptor class C group 5 member D (GPRC5D), CD3 receptor on T-cells
Mechanism
Immune activation, directed at G protein-coupled receptor class C group 5 member D (GPRC5D) and CD3 receptor on T-cells
Pathways
T-cell activation, proinflammatory cytokine release, lysis of multiple myeloma cells
Therapy area
Oncology
Developer
Janssen Biotech (JNJ)
FDA status
Approved as Talvey (August 9, 2023), BLA761342 · FDA label
UNII
4W3KFI3TN3

✅ FDA-approved uses

From the indications section of the FDA label (version of Oct 8, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07649525 Phase 3 Multiple Myeloma (MM) Recruiting JNJ

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cytokine Release SyndromeRecurrent Multiple MyelomaRefractory Multiple Myeloma

Other drugs acting on GPRC5D

More from Janssen Biotech

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the JNJ page.

Follow JNJ, the company behind Talquetamab

See JNJ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

JNJ catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.